20/20 Biolabs, Inc.
AIDX
$1.46
$0.096.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 28.78% | -23.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 28.78% | -23.22% | |||
| Cost of Revenue | 49.47% | -28.17% | |||
| Gross Profit | -10.13% | -11.79% | |||
| SG&A Expenses | 12.10% | 0.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.12% | -9.99% | |||
| Operating Income | -14.07% | 1.08% | |||
| Income Before Tax | -58.43% | -2.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -58.43% | -2.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -58.43% | -2.83% | |||
| EBIT | -14.07% | 1.08% | |||
| EBITDA | -14.58% | 0.95% | |||
| EPS Basic | -50.18% | -1.20% | |||
| Normalized Basic EPS | -50.19% | -1.15% | |||
| EPS Diluted | -50.89% | -1.20% | |||
| Normalized Diluted EPS | -50.19% | -1.15% | |||
| Average Basic Shares Outstanding | 5.48% | 1.66% | |||
| Average Diluted Shares Outstanding | 5.48% | 1.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||